Clovis’s Rubraca Is First PARP For Prostate Cancer, But AZ’s Lynparza Coming Soon
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.